Skip to main content

Advertisement

Fig. 2 | Respiratory Research

Fig. 2

From: Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis

Fig. 2

Treatment effect of budesonide added to formoterol on time to first CID by study. Treatment effect of budesonide (BUD) added to formoterol (FORM) on time to first CID by study (full study duration and censored at 6 months and 3 months); an early CID, within the first 3–6 months of study commencement, has been suggested to be predictive of future outcomes such as mortality, lung function decline rate and exacerbations. Therefore, data primarily based on full study length was analysed, but analyses were also conducted on data censored at 6 months (Day 180) and 3 months (Day 90). BUD, budesonide; CID, Clinically Important Deterioration; CI, confidence interval; FORM, formoterol; HR, hazard ratio

Back to article page